Phase 2 N=23 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
Papillary Thyroid Cancer · Follicular Thyroid Cancer · Differentiated Thyroid Cancer
Primary: Progression Free Survival — 241 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=47 N-Acetylcysteine for Neuroprotection in Parkinson's Disease
Parkinson Disease
Primary: Change of Cerebral Glutathione Levels as Measured by Proton Magnetic Resonance Spectroscopy — 3.422; 3.334; 3.745; 4.282 Ratio
Phase 2 N=43 A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Carcinoma · Neuroendocrine Tumors
Primary: Percentage of Participants With Progression-Free Survival (PFS) Rate at Six Months — 45.2; 41.7; 54.1; 61.4 percentage of participants
Phase 2 N=213 A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy
Chronic Obstructive Pulmonary Disease COPD
Primary: Time to First Moderate to Severe COPD Exacerbation or Early Drop-out Related to Worsening of COPD Symptoms — NA; 118.0 days — p=0.2371
Phase 2 N=16 Paediatric Safety Study in Cat-PAD
Rhinoconjunctivitis
Primary: Number of Subjects With AEs — 5; 12 participants
Phase 2 N=50 A Study for Participants With Pancreatic Cancer
Pancreatic Neoplasms
Primary: Phase 1: Determine the Recommended Phase 2 Dose for LY2603618 When Administered After Gemcitabine — 230 milligrams (mg)
Phase 2 N=138 A Study for Patients With Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Daily Average Blood Glucose (Avg. BG) at Week 8 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles — 7.98; 8.53 millimole per Liter…
Phase 2 N=205 Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons
Alcohol Abuse · Alcohol Dependence
Primary: Number of Alcoholic Containing Drinks Per Drinking Day — 5.9; 6.1; 5.9 Standard alcohol drinks per drinking day
Phase 2 N=396 Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
Meningococcal B Disease
Primary: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria…
Phase 2 N=24 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
Transverse Myelitis · Neuromyelitis Optica · Idiopathic Transverse Myelitis
Primary: Walking Speed During Timed 25-foot Walk — 0.3342; 0.4745; 0.4593; 0.1743 feet/second
Phase 2 N=21 Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.
Pregnancy Complications
Primary: Number of Participants With Achievement of 34 Weeks Gestation — 0; 0 Participants
Phase 2 N=12 Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
Ocular Hypertension · Open Angle Glaucoma
Primary: Change in Intraocular Pressure (IOP) Over Nocturnal Time Period — 22.84; 23.56; 19.38; 23.19 mmHg
Phase 2 N=338 A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)
Pneumococcal Infections
Primary: Adults: Percentage of Participants With an Adverse Event — 90.0; 95.0; 95.0; 95.0 Percentage of participants
Phase 2 N=224 Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
Ocular Hypertension · Open Angle Glaucoma
Primary: Intraocular Pressure (IOP) — 27.34; 27.11; 26.78; 25.55 mmHg
Phase 2 N=103 Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)
Acute Myocardial Infarction
Primary: Infarct Size on Baseline Cardiac Magnetic Resonance Imaging (cMRI) — 20.1; 21.0 ml — p=0.90